Middle East Respiratory Syndrome (MERS) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Middle East Respiratory Syndrome (MERS) – Pipeline Review, H1 2020’, provides an overview of the Middle East Respiratory Syndrome (MERS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS)

– The report reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Middle East Respiratory Syndrome (MERS) therapeutics and enlists all their major and minor projects

– The report assesses Middle East Respiratory Syndrome (MERS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Middle East Respiratory Syndrome (MERS)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AIM ImmunoTech Inc

Anglo Biopharma Ltd

Atriva Therapeutics GmbH

Autoimmune Technologies LLC

Celltrion Inc

Chongqing Zhifei Biological Products Co Ltd

Cocrystal Pharma Inc

Future Medicine Co Ltd

Gilead Sciences Inc

Global BioLife Inc Ltd

Greffex Inc

Humabs BioMed SA

Inovio Pharmaceuticals Inc

LegoChem Biosciences Inc

NanoViricides Inc

Novavax Inc

Orgenesis Inc

Ostrich Pharma USA Inc

OyaGen Inc

Phelix Therapeutics LLC

Pulmotect Inc

Regeneron Pharmaceuticals Inc

Ridgeback Biotherapeutics LP

Romark Laboratories LC

SAB Biotherapeutics Inc

Signia Therapeutics

AIkido Pharma Inc

Sumagen Co Ltd

Themis Bioscience GmbH

Theravectys SA

Vaccitech Ltd

VBI Vaccines Inc

Table of Contents

Table of Contents

Introduction

Middle East Respiratory Syndrome (MERS) - Overview

Middle East Respiratory Syndrome (MERS) - Therapeutics Development

Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment

Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development

Middle East Respiratory Syndrome (MERS) - Drug Profiles

Middle East Respiratory Syndrome (MERS) - Dormant Projects

Middle East Respiratory Syndrome (MERS) - Discontinued Products

Middle East Respiratory Syndrome (MERS) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by AIM ImmunoTech Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Anglo Biopharma Ltd, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Atriva Therapeutics GmbH, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Autoimmune Technologies LLC, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Celltrion Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Cocrystal Pharma Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Future Medicine Co Ltd, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Gilead Sciences Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Global BioLife Inc Ltd, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Greffex Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Humabs BioMed SA, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Inovio Pharmaceuticals Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by LegoChem Biosciences Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by NanoViricides Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Novavax Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Orgenesis Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Ostrich Pharma USA Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by OyaGen Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Phelix Therapeutics LLC, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Pulmotect Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Ridgeback Biotherapeutics LP, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Romark Laboratories LC, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by SAB Biotherapeutics Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Signia Therapeutics, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by AIkido Pharma Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Sumagen Co Ltd, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Themis Bioscience GmbH, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Theravectys SA, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by Vaccitech Ltd, H1 2020

Middle East Respiratory Syndrome (MERS) – Pipeline by VBI Vaccines Inc, H1 2020

Middle East Respiratory Syndrome (MERS) – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports